Rachel Melanie Reeves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rachel Melanie Reeves has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Richard Pebody
World Health Organization Regional Office for Europe
4 shared publications Alen Marijam
GSK, Wavre, Belgium
3 shared publicationsHarish Nair
Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China
3 shared publications- Pia Hardelid
GOS Institute of Child Health, University College London, London, UK
3 shared publications - Ruth Gilbert
University College London
3 shared publications - Triantafyllos Pliakas
Impact Epilysis
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Infection
- p. 1-16
Respiratory syncytial virus in adults aged ≥ 50 years in the Netherlands: a database and time-series modelling analysis (2013–2020)
Purpose: Respiratory syncytial virus (RSV) is a significant yet historically understudied contributor to acute respiratory infection (ARI) in older adults. This study aimed to quantify ARI-associated hospital admissions and estimate RSV-related burden of disease in secondary care in the Netherlands using time-series modelling. Methods: This retrospective cohort study (1 July 2013 to 29 February 2020) utilised routinely collected primary and secondary care data from the PHARMO Data Network. ARI-associated hospital admissions in patients aged ≥ 50 years, identified via International Classification of Diseases (ICD)-10 codes, were described in terms of patient and clinical characteristics and healthcare resource utilisation. The number and annual rate of RSV- and influenza-associated ARI and lower respiratory tract disease (LRTD) hospital admissions by age and risk group were estimated using a Quasi-Poisson regression model. Results: There were 97,279 ARI admissions in 63,420 patients. Estimated RSV-associated ARI hospital admission rates ranged from 0.70/1,000 person-years (PY) to 1.92/1,000 PY in adults aged ≥ 50 and ≥ 75, respectively. RSV-associated LRTD admissions varied from 0.63/1,000 PY to 1.73/1,000 PY in these groups. Hospitalisation rates were higher in high-risk individuals. Estimated RSV admissions were up to six times higher than observed. During peak months, up to 30% of ARI (20% of LRTD) admissions were attributable to RSV. RSV-coded admissions had an average length of stay of 7–8 days, and 30% of patients experienced all-cause readmission within 90 days. Conclusion: The substantial hospitalisation burden of RSV calls for prioritisation of RSV prevention strategies, including vaccination, alongside influenza and other causes of ARI and LRTD.
- 26 October 2026
- Published by Springer Nature in Infection
- p. 1-16
Open AccessRespiratory syncytial virus in adults aged ≥ 50 years in the Netherlands: a database and time-series modelling analysis (2013–2020)
Purpose: Respiratory syncytial virus (RSV) is a significant yet historically understudied contributor to acute respiratory infection (ARI) in older adults. This study aimed to quantify ARI-associated hospital admissions and estimate RSV-related burden of disease in secondary care in the Netherlands using time-series modelling. Methods: This retrospective cohort study (1 July 2013 to 29 February 2020) utilised routinely collected primary and secondary care data from the PHARMO Data Network. ARI-associated hospital admissions in patients aged ≥ 50 years, identified via International Classification of Diseases (ICD)-10 codes, were described in terms of patient and clinical characteristics and healthcare resource utilisation. The number and annual rate of RSV- and influenza-associated ARI and lower respiratory tract disease (LRTD) hospital admissions by age and risk group were estimated using a Quasi-Poisson regression model. Results: There were 97,279 ARI admissions in 63,420 patients. Estimated RSV-associated ARI hospital admission rates ranged from 0.70/1,000 person-years (PY) to 1.92/1,000 PY in adults aged ≥ 50 and ≥ 75, respectively. RSV-associated LRTD admissions varied from 0.63/1,000 PY to 1.73/1,000 PY in these groups. Hospitalisation rates were higher in high-risk individuals. Estimated RSV admissions were up to six times higher than observed. During peak months, up to 30% of ARI (20% of LRTD) admissions were attributable to RSV. RSV-coded admissions had an average length of stay of 7–8 days, and 30% of patients experienced all-cause readmission within 90 days. Conclusion: The substantial hospitalisation burden of RSV calls for prioritisation of RSV prevention strategies, including vaccination, alongside influenza and other causes of ARI and LRTD.
- Open Access
- 10 July 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2675075
RSV-related hospital admissions in a subset of hospitals in England and Scotland: A real-world study (2018–2023)
Respiratory syncytial virus (RSV) is a seasonal respiratory virus associated with a high risk of hospitalization and mortality, particularly among older adults and those with chronic conditions.1–3...
- 10 July 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2675075
Open AccessRSV-related hospital admissions in a subset of hospitals in England and Scotland: A real-world study (2018–2023)
Respiratory syncytial virus (RSV) is a seasonal respiratory virus associated with a high risk of hospitalization and mortality, particularly among older adults and those with chronic conditions.1–3...
- Open Access
- 26 May 2026
- Published by Taylor & Francis in Pulmonology
- Vol. 32 (1) , 2671584
Clinical and economic burden of respiratory syncytial virus among adults hospitalised with acute respiratory infections in Portugal
Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI) in older adults,1,2 especially during winter.2,3 RSV-ARI is associated with substantial morbidity and mo...
- 26 May 2026
- Published by Taylor & Francis in Pulmonology
- Vol. 32 (1) , 2671584
Open AccessClinical and economic burden of respiratory syncytial virus among adults hospitalised with acute respiratory infections in Portugal
Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI) in older adults,1,2 especially during winter.2,3 RSV-ARI is associated with substantial morbidity and mo...
- Open Access
- 20 March 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2638638
Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study
Respiratory syncytial virus (RSV) is, like influenza, one of the most common causes of severe acute respiratory infections (ARIs) in adults; however, its incidence across different risk and age groups is unknown. We estimated the incidence of registered ARIs in Danish adults, focusing on RSV and contextualizing with influenza. We conducted a nationwide cohort study in Denmark, including all adults aged ≥18 y with a registered ARI, during the 2011/12 to 2022/23 seasons. We estimated the incidence (per 100,000 person-years) of ARI overall and ARI attributable to RSV or influenza, overall and stratified by sex, age, and comorbidity. We identified 962,858 ARIs, of which 10,437 (1.1%) were attributed to RSV and 62,869 (6.5%) to influenza. The ARI incidence increased over time (range: 1,272-2,144), including a rise in RSV incidence (range: 0.2-91.6), while influenza incidence fluctuated (range: 6.7-322.0). In the 2022/23 season, RSV incidence was higher among females, older adults (198.7 in ≥60-y-olds, and 303.2 in ≥75-y-olds), and those with comorbidities, especially hematologic disease (868.6) and chronic obstructive pulmonary disease (679.5). Although influenza incidence was generally higher than RSV, the incidences were comparable for older adults and those with comorbidities. In conclusion, RSV is an important cause of ARIs among adults, comparable to influenza, particularly in older adults and those with comorbidities. These findings underscore the substantial burden of RSV that is relevant for public health planning and clinical decision-making, particularly given the recent approval of three highly effective RSV vaccines.
- 20 March 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2638638
Open AccessIncidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study
Respiratory syncytial virus (RSV) is, like influenza, one of the most common causes of severe acute respiratory infections (ARIs) in adults; however, its incidence across different risk and age groups is unknown. We estimated the incidence of registered ARIs in Danish adults, focusing on RSV and contextualizing with influenza. We conducted a nationwide cohort study in Denmark, including all adults aged ≥18 y with a registered ARI, during the 2011/12 to 2022/23 seasons. We estimated the incidence (per 100,000 person-years) of ARI overall and ARI attributable to RSV or influenza, overall and stratified by sex, age, and comorbidity. We identified 962,858 ARIs, of which 10,437 (1.1%) were attributed to RSV and 62,869 (6.5%) to influenza. The ARI incidence increased over time (range: 1,272-2,144), including a rise in RSV incidence (range: 0.2-91.6), while influenza incidence fluctuated (range: 6.7-322.0). In the 2022/23 season, RSV incidence was higher among females, older adults (198.7 in ≥60-y-olds, and 303.2 in ≥75-y-olds), and those with comorbidities, especially hematologic disease (868.6) and chronic obstructive pulmonary disease (679.5). Although influenza incidence was generally higher than RSV, the incidences were comparable for older adults and those with comorbidities. In conclusion, RSV is an important cause of ARIs among adults, comparable to influenza, particularly in older adults and those with comorbidities. These findings underscore the substantial burden of RSV that is relevant for public health planning and clinical decision-making, particularly given the recent approval of three highly effective RSV vaccines.
- Open Access
- 4 August 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-12
Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis
Background: With respiratory syncytial virus vaccines recently approved for use among older adults, country-level respiratory syncytial virus (RSV) disease burden estimates are needed to inform local RSV immunisation strategy. We aimed to estimate country-level RSV hospitalisation burden in older adults in Europe. Methods: We compiled data on RSV hospitalisation burden in adults aged ≥ 60 years in Europe from published studies (systematic review: PROSPERO CRD42024516945), surveillance data, and unpublished data from international collaborators. We adjusted for diagnostic testing, clinical specimens, and case definitions through statistical modelling techniques and generated country-level hospitalisation rate estimates; for countries with no available data, we developed an ensemble model to predict RSV hospitalisation rates. We also estimated RSV in-hospital case fatality ratio (hCFR) for countries with available data. Results: We included 14 studies (3 unpublished studies). The adjusted RSV-associated hospitalisation rates were overall 2.2 to 6.4 times higher than unadjusted estimates. Among 5 countries with available data, adjusted annual RSV hospitalisation rates ranged from 193/100,000 person-years in the Netherlands (95% confidence interval [CI]: 125–304) and Finland (141–274) to 414/100,000 in Denmark (322–514). The RSV hospitalisation rates predicted by the ensemble model in 23 additional countries ranged from 223/100,000 to 317/100,000 person-years. RSV hCFR ranged from 6.73% (4.63–9.69) in Spain to 10.14% (4.91–19.79) in Switzerland. Conclusions: This study addresses knowledge gaps in RSV hospitalisation burden among older adults in Europe while highlighting the importance of adjusting for RSV case under-ascertainment. These findings might be relevant for country’s considerations of RSV immunisation strategies for older adults. Graphical
- 4 August 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-12
Open AccessEstimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis
Background: With respiratory syncytial virus vaccines recently approved for use among older adults, country-level respiratory syncytial virus (RSV) disease burden estimates are needed to inform local RSV immunisation strategy. We aimed to estimate country-level RSV hospitalisation burden in older adults in Europe. Methods: We compiled data on RSV hospitalisation burden in adults aged ≥ 60 years in Europe from published studies (systematic review: PROSPERO CRD42024516945), surveillance data, and unpublished data from international collaborators. We adjusted for diagnostic testing, clinical specimens, and case definitions through statistical modelling techniques and generated country-level hospitalisation rate estimates; for countries with no available data, we developed an ensemble model to predict RSV hospitalisation rates. We also estimated RSV in-hospital case fatality ratio (hCFR) for countries with available data. Results: We included 14 studies (3 unpublished studies). The adjusted RSV-associated hospitalisation rates were overall 2.2 to 6.4 times higher than unadjusted estimates. Among 5 countries with available data, adjusted annual RSV hospitalisation rates ranged from 193/100,000 person-years in the Netherlands (95% confidence interval [CI]: 125–304) and Finland (141–274) to 414/100,000 in Denmark (322–514). The RSV hospitalisation rates predicted by the ensemble model in 23 additional countries ranged from 223/100,000 to 317/100,000 person-years. RSV hCFR ranged from 6.73% (4.63–9.69) in Spain to 10.14% (4.91–19.79) in Switzerland. Conclusions: This study addresses knowledge gaps in RSV hospitalisation burden among older adults in Europe while highlighting the importance of adjusting for RSV case under-ascertainment. These findings might be relevant for country’s considerations of RSV immunisation strategies for older adults. Graphical
- Open Access
- 3 April 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 61 (4) , 2201569
New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic
Learning from the COVID-19 pandemic and considering the effects of this pandemic, we provide recommendations that can guide towards sustainable RSV surveillance with the potential to be integrated into the broader perspective of respiratory surveillance. https://bit.ly/40TsO0G
- 3 April 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 61 (4) , 2201569
Open AccessNew perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic
Learning from the COVID-19 pandemic and considering the effects of this pandemic, we provide recommendations that can guide towards sustainable RSV surveillance with the potential to be integrated into the broader perspective of respiratory surveillance. https://bit.ly/40TsO0G
- Open Access
- 17 October 2021
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 16 (1) , 125-131
Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England
Respiratory syncytial virus (RSV) is a common seasonal respiratory virus and an important cause of illness among infants, but the burden of RSV disease is not well described among the older population. The objective of this study was to estimate the age‐specific incidence of hospital admission among over 65 s due to respiratory illnesses attributable to RSV in England to inform optimal vaccine and therapeutic interventions.We used linear multiple regression to examine the effect of changes in weekly counts of respiratory pathogens on the weekly counts of respiratory hospital admissions. The study population was all patients aged 65 years or over admitted to English hospitals between 2nd August 2010 and 30th July 2017.RSV was estimated to account for a seasonal annual average of 71 (95% CI 52–90) respiratory admissions per 100 000 in adults age 65–74 and 251 (95% CI 186–316) admissions per 100,000 adults age 75+. Pneumococcus was the pathogen responsible for highest annual average respiratory admission with 448 (95% CI 310–587) admissions per 100,000 adults age 65–74 and 1010 (95% CI 527–1493) admissions per 100,000 adults aged 75+.This study shows that RSV continues to exert a significant burden of disease among older adults in England. These findings will support development of policy for the use of RSV therapeutics and vaccines in this age group.
- 17 October 2021
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 16 (1) , 125-131
Open AccessEstimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England
Respiratory syncytial virus (RSV) is a common seasonal respiratory virus and an important cause of illness among infants, but the burden of RSV disease is not well described among the older population. The objective of this study was to estimate the age‐specific incidence of hospital admission among over 65 s due to respiratory illnesses attributable to RSV in England to inform optimal vaccine and therapeutic interventions.We used linear multiple regression to examine the effect of changes in weekly counts of respiratory pathogens on the weekly counts of respiratory hospital admissions. The study population was all patients aged 65 years or over admitted to English hospitals between 2nd August 2010 and 30th July 2017.RSV was estimated to account for a seasonal annual average of 71 (95% CI 52–90) respiratory admissions per 100 000 in adults age 65–74 and 251 (95% CI 186–316) admissions per 100,000 adults age 75+. Pneumococcus was the pathogen responsible for highest annual average respiratory admission with 448 (95% CI 310–587) admissions per 100,000 adults age 65–74 and 1010 (95% CI 527–1493) admissions per 100,000 adults aged 75+.This study shows that RSV continues to exert a significant burden of disease among older adults in England. These findings will support development of policy for the use of RSV therapeutics and vaccines in this age group.
- Open Access
- 22 April 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (3) , 2003766
Recommendations for respiratory syncytial virus surveillance at the national level
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections and hospitalisations among young children and is globally responsible for many deaths in young children, especially in infants aged <6 months. Furthermore, RSV is a common cause of severe respiratory disease and hospitalisation among older adults. The development of new candidate vaccines and monoclonal antibodies highlights the need for reliable surveillance of RSV. In the European Union (EU), no up-to-date general recommendations on RSV surveillance are currently available. Based on outcomes of a workshop with 29 European experts in the field of RSV virology, epidemiology and public health, we provide recommendations for developing a feasible and sustainable national surveillance strategy for RSV that will enable harmonisation and data comparison at the European level. We discuss three surveillance components: active sentinel community surveillance, active sentinel hospital surveillance and passive laboratory surveillance, using the EU acute respiratory infection and World Health Organization (WHO) extended severe acute respiratory infection case definitions. Furthermore, we recommend the use of quantitative reverse transcriptase PCR-based assays as the standard detection method for RSV and virus genetic characterisation, if possible, to monitor genetic evolution. These guidelines provide a basis for good quality, feasible and affordable surveillance of RSV. Harmonisation of surveillance standards at the European and global level will contribute to the wider availability of national level RSV surveillance data for regional and global analysis, and for estimation of RSV burden and the impact of future immunisation programmes.
- 22 April 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (3) , 2003766
Open AccessRecommendations for respiratory syncytial virus surveillance at the national level
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections and hospitalisations among young children and is globally responsible for many deaths in young children, especially in infants aged <6 months. Furthermore, RSV is a common cause of severe respiratory disease and hospitalisation among older adults. The development of new candidate vaccines and monoclonal antibodies highlights the need for reliable surveillance of RSV. In the European Union (EU), no up-to-date general recommendations on RSV surveillance are currently available. Based on outcomes of a workshop with 29 European experts in the field of RSV virology, epidemiology and public health, we provide recommendations for developing a feasible and sustainable national surveillance strategy for RSV that will enable harmonisation and data comparison at the European level. We discuss three surveillance components: active sentinel community surveillance, active sentinel hospital surveillance and passive laboratory surveillance, using the EU acute respiratory infection and World Health Organization (WHO) extended severe acute respiratory infection case definitions. Furthermore, we recommend the use of quantitative reverse transcriptase PCR-based assays as the standard detection method for RSV and virus genetic characterisation, if possible, to monitor genetic evolution. These guidelines provide a basis for good quality, feasible and affordable surveillance of RSV. Harmonisation of surveillance standards at the European and global level will contribute to the wider availability of national level RSV surveillance data for regional and global analysis, and for estimation of RSV burden and the impact of future immunisation programmes.
- Open Access
- 6 January 2017
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 11 (2) , 122-129
Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007‐2012
Background: Respiratory syncytial virus (RSV) is a leading cause of hospital admission in young children. With several RSV vaccines candidates undergoing clinical trials, recent estimates of RSV burden are required to provide a baseline for vaccine impact studies.Objectives: To estimate the number of RSV‐associated hospital admissions in children aged <5 years in England over a 5‐year period from 2007 using ecological time series modelling of national hospital administrative data.Patients/Methods: Multiple linear regression modelling of weekly time series of laboratory surveillance data and Hospital Episode Statistics (HES) data was used to estimate the number of hospital admissions due to major respiratory pathogens including RSV in children <5 years of age in England from mid‐2007 to mid‐2012, stratified by age group (<6 months, 6‐11 months, 1‐4 years) and primary diagnosis: bronchiolitis, pneumonia, unspecified lower respiratory tract infection (LRTI), bronchitis and upper respiratory tract infection (URTI).Results: On average, 33 561 (95% confidence interval 30 429‐38 489) RSV‐associated hospital admissions in children <5 years of age occurred annually from 2007 to 2012. Average annual admission rates were 35.1 (95% CI: 32.9‐38.9) per 1000 children aged <1 year and 5.31 (95% CI: 4.5‐6.6) per 1000 children aged 1‐4 years. About 84% (95% CI: 81‐91%) of RSV‐associated admissions were for LRTI. The diagnosis‐specific burden of RSV‐associated admissions differed significantly by age group.Conclusions: RSV remains a significant cause of hospital admissions in young children in England. Individual‐level analysis of RSV‐associated admissions is required to fully describe the burden by age and risk group and identify optimal prevention strategies.
- 6 January 2017
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 11 (2) , 122-129
Open AccessEstimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007‐2012
Background: Respiratory syncytial virus (RSV) is a leading cause of hospital admission in young children. With several RSV vaccines candidates undergoing clinical trials, recent estimates of RSV burden are required to provide a baseline for vaccine impact studies.Objectives: To estimate the number of RSV‐associated hospital admissions in children aged <5 years in England over a 5‐year period from 2007 using ecological time series modelling of national hospital administrative data.Patients/Methods: Multiple linear regression modelling of weekly time series of laboratory surveillance data and Hospital Episode Statistics (HES) data was used to estimate the number of hospital admissions due to major respiratory pathogens including RSV in children <5 years of age in England from mid‐2007 to mid‐2012, stratified by age group (<6 months, 6‐11 months, 1‐4 years) and primary diagnosis: bronchiolitis, pneumonia, unspecified lower respiratory tract infection (LRTI), bronchitis and upper respiratory tract infection (URTI).Results: On average, 33 561 (95% confidence interval 30 429‐38 489) RSV‐associated hospital admissions in children <5 years of age occurred annually from 2007 to 2012. Average annual admission rates were 35.1 (95% CI: 32.9‐38.9) per 1000 children aged <1 year and 5.31 (95% CI: 4.5‐6.6) per 1000 children aged 1‐4 years. About 84% (95% CI: 81‐91%) of RSV‐associated admissions were for LRTI. The diagnosis‐specific burden of RSV‐associated admissions differed significantly by age group.Conclusions: RSV remains a significant cause of hospital admissions in young children in England. Individual‐level analysis of RSV‐associated admissions is required to fully describe the burden by age and risk group and identify optimal prevention strategies.